You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
In their first conference call with investors, PacBio's new CEO and CFO laid out a strategic plan for the company as it weathers the COVID-19 pandemic.
At the ASHG 2020 virtual meeting, researchers presented data showing they could use the method to enrich for placental DNA in maternal plasma samples.
Though Guardant and Foundation have pioneered a path through the FDA for liquid biopsy tests, label differences highlight complex choices for oncologists.
Illumina reported total third quarter revenues of $794 million. On the investor conference call, Illumina's CEO justified the $8 billion Grail deal.
The firm's CLIA lab presented data at the virtual ASHG meeting showing how it validated WGS-based STR expansion analysis to diagnose rare disease.
The funds will support continued growth in precision oncology, new product development, and new initiatives in the clinical trial and biopharmaceutical markets.
The findings demonstrate the value of multi-cohort platform trials as an option for refractory cancer patients with particularly rare genomic tumor alterations.
Under the agreement, Intermountain will be able to implement Kailos' PGxComplete next-generation sequencing methodology in its laboratory for pharmacogenetic testing.
Sema4 will use its genomics testing abilities and Centrellis health intelligence platform to identify eligible patients for Janssen's oncology clinical trials.
In the study, thirty percent of patients receiving a genome sequencing test obtained a new primary molecular genetic diagnosis.
The program is in its third year monitoring individuals with these mutations to try to detect disease early, understand their risk, and develop preventive treatments.
Ambry will provide RNA sequencing for Scipher's PrismRA blood test to predict response to TNF inhibitor therapies in rheumatoid arthritis patients.
The investment banking firm forecast Fiscal Year 2021 revenues of $235.6 million, higher than the consensus Wall Street estimate of $178.4 million.
GeneDx will provide whole-exome and whole-genome sequencing, among other services, to neonatal intensive care units staffed with Pediatrix-affiliated doctors.
The immune sequencing firm also provided an update on the development of its ImmunoSeq Dx clinical product for detecting prior infection with SARS-CoV-2.
The in vitro diagnostic test runs on the Illumina NovaSeq 6000 instrument and will be performed at Helix's San Diego CLIA-certified laboratory.
The sequencing firm said infectious disease research, diagnostics, screening, and surveillance could all increase demand for its NGS products.
The service is the first of its kind in the UK and relies on the Illumina NovaSeq 6000 platform to deliver results.
The San Diego-based genomic analysis firm said the decline in revenues was due to the impact of the COVID-19 pandemic on research customers.
The sequencing-based test for minimal residual disease can be use with blood and bone marrow samples in patients with chronic lymphocytic leukemia.
Reuters reports that Germany is seeking to sequence 5 percent of patient samples that test positive for SARS-CoV-2.
23andMe and Medscape say primary care physicians are increasingly more comfortable with discussing direct-to-consumer genetic testing results.
The publisher of the Science family of journals will allow some authors to place peer-reviewed versions of their papers into publicly accessible repositories.
In Science this week: analysis of genome-wide association studies of chronic kidney disease, and more.